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ABSTRACT
Introduction People with severe mental illness (SMI) 
die on average 10–20 years earlier than the general 
population. Most of these deaths are due to physical 
health conditions. The aim of this cross- sectional study is 
to determine the prevalence of physical health conditions 
and their associations with health- risk behaviours, 
health- related quality of life and various demographic, 
behavioural, cognitive, psychological and social variables 
in people with SMI attending specialist mental health 
facilities in South Asia.
Methods and analysis We will conduct a survey of 
patients with SMI attending specialist mental health 
facilities in Bangladesh, India and Pakistan (n=4500). 
Diagnosis of SMI will be confirmed using the Mini- 
international neuropsychiatric interview V.6.0. We will 
collect information about physical health and related 
health- risk behaviours (WHO STEPwise approach to 
Surveillance (STEPS)); severity of common mental 
disorders (Patient Health Questionnaire-9 (PHQ-9) and 
General Anxiety Disorder scale (GAD-7)) and health- related 
quality of life (EQ- 5D- 5L). We will measure blood pressure, 
height, weight and waist circumference according to WHO 
guidelines. We will also measure glycated haemoglobin, 
lipid profile, thyroid function, liver function, creatinine 
and haemoglobin. Prevalence rates of physical health 
conditions and health- risk behaviours will be presented 
and compared with the WHO STEPS survey findings in the 
general population. Regression analyses will explore the 
association between health- risk behaviours, mental and 
physical health conditions.
Ethics and dissemination The study has been 
approved by the ethics committees of the Department 
of Health Sciences University of York (UK), Centre for 
Injury Prevention and Rehabilitation (Bangladesh), Health 
Ministry Screening Committee and Indian Council of 
Medical Research (India) and National Bioethics Committee 
(Pakistan). Findings will be disseminated in peer- reviewed 
articles, in local and international conferences and as 
reports for policymakers and stakeholders in the countries 
involved.
Trial registration number ISRCTN88485933; 3 June 
2019.
BACKGROUND
A considerable body of research has shown 
that people with severe mental illness (SMI; 
that is, psychotic disorders, bipolar affec-
tive disorder and severe depression with 
psychotic symptoms) die on average 10–20 
years earlier than the general population.1 2 
Around 80% of deaths in people with SMI are 
due to preventable physical illnesses, most 
commonly cardiometabolic diseases, respira-
tory disorders and infectious diseases.3 4This 
excess mortality is a major global public health 
challenge but efforts to address it have been 
limited. Recent studies suggest that despite 
an overall improvement in life expectancy for 
both the general population and people with 
Strengths and limitations of this study
 ► The study uses standardised tools to measure pa-
tient outcomes that will allow us to compare the 
findings with those of the general population.
 ► The survey will be conducted face to face by trained 
researchers.
 ► The questionnaire has been translated into the most 
common languages used in Bangladesh, India and 
Pakistan using validated translations of standardised 
measures where available.
 ► The survey is being conducted in specialist cen-
tres and is therefore a healthcare utilisation sample 
drawn largely from tertiary care.
 ► The study population may not be representative of 
all the people with severe mental illness in each 
country, as those not accessing specialist centres 
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SMI, the absolute mortality gap between these two groups 
is actually widening.5–7
Prevalence of most physical health conditions is higher 
and outcomes are poorer in this population.8 Multimor-
bidity (the presence of two or more conditions) is also 
more common9 in the presence of SMI, contributing to 
poorer physical health and quality of life. The majority of 
evidence for these health inequalities has been generated 
in high- income countries (HICs), but a small number of 
studies from low- income and middle- income countries 
(LMICs) also show a similar pattern of increased mortality 
for people with SMI, with an even shorter life expectancy, 
and larger mortality gap.4 10–12 The few studies available 
suggest that physical comorbidity in SMI is at least as prev-
alent as in developed countries.1
In South Asia, rates of mental illness and physical non- 
communicable diseases have been increasing rapidly.13 14 
This increase, coupled with the lack of access to even basic 
mental healthcare,15 and neglect of the physical health 
needs of people with SMI by policymakers and healthcare 
services,16 means that the burden of disease due to phys-
ical disorders in people with mental illness. is set to rise 
further, with a corresponding increase within country and 
global health inequalities. This increase is coupled with a 
recognised lack of information about the prevalence of 
physical conditions and health risk behaviours in the SMI 
population in South Asia.17 This gap in knowledge, partic-
ularly in relation to health service planning in LMICs, has 
been pointed out repeatedly as a priority for research.18 
Addressing mental and physical health comorbidity in 
LMICs is also a global priority, recognised in global poli-
cies to help achieve the sustainable development goals, 
including ‘ensuring healthy lives and promoting well- 
being for all’.19–21 A detailed understanding of the preva-
lence of physical health conditions, health risk behaviours 
and health service utilisation in SMI in LMICs is needed 
to progress this agenda.22
Objectives
In people with SMI attending specialist mental health 
facilities:
1. Determine the prevalence of physical health condi-
tions (ie, type 2 diabetes, hypertension, heart disease, 
obesity and infectious diseases) and health- risk be-
haviours (ie, diet, physical activity, alcohol and tobacco 
use) and compare these findings with those reported 
in the general population.
2. Determine the association between physical health 
conditions, health- risk behaviours, health- related qual-
ity of life and various demographic, behavioural, cog-
nitive, psychological and social variables.
3. Identify health- service utilisation and the type of life-
style advice that has been offered for this population.
4. Support clinical trial readiness by providing evidence- 
based findings regarding outcome measures and pro-
cedures relevant for clinical trial design.
METHODS AND ANALYSIS
Design, settings and population
We will conduct a cross- sectional survey among patients 
with a clinical diagnosis of SMI recruited at national 
specialist mental health institutions. In Bangladesh, 
the study will be conducted at the National Institute of 
Mental Health and Hospital (NIMHH) in Dhaka. NIMHH 
offers 200 beds for in- patient care and on average 400 
outpatients attend every day. In India, the study will be 
conducted at the National Institute of Mental Health 
and Neurosciences (NIMHANS) in Bengaluru, with 650 
beds for in- patient care; on average at NIMHANS, 400 
outpatients attend every day. In Pakistan, the study will 
be conducted at the Institute of Psychiatry (IOP) Rawal-
pindi Medical University, a WHO collaborating centre 
for the Eastern Mediterranean . IOP offers 60 beds for 
inpatients and on average 400 outpatients attend every 
day. All three national institutes serve patients from all 
over the country. Adults (18 years and over) with a clinical 
diagnosis of SMI (defined by the International Classifica-
tion of Disease 10th revision (ICD-1023) as schizophrenia, 
schizotypal and delusional disorders (F20- F29); bipolar 
affective disorder (F30, F31) and severe depression with 
psychotic symptoms (F32.3, F33.3)),23 who are able to 
provide informed consent as assessed by the treating 
clinician will be recruited. Patients who lack capacity to 
provide consent or are unable to complete study ques-
tionnaires will be excluded (figure 1). The data will be 
collected from June 2019 to September 2020.
Sample size
We aim to build as large a sample as possible within the 
resources available over the study period (n=1500 per 
country). As an indicative example of survey precision to 
address some of the key research questions, we provide a 
sample size estimate for investigating the prevalence of 
diabetes. Assuming a prevalence estimate of 10% (based 
on results from previous studies,24 we will need 857 partic-
ipants per country to achieve ±2% precision assuming a 
95% CI.25
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Recruitment and random selection of the participants
Both inpatients and outpatients attending one of the 
three specialist mental health institutions collaborating 
in this study will be recruited. At NIMHH and NIMHANS, 
patients will be selected randomly using random number 
tables generated centrally to determine for outpatients, 
which patient to approach on a given day, and for inpa-
tients by randomly selecting beds. Recruitment is sepa-
rated by inpatients versus outpatients, resulting in a 
proportion of 80% outpatients and 20% inpatients (which 
has been reported as the ‘usual’ proportion of inpatients 
and outpatients). Due to the lower volume of patients and 
outpatients reaching the centre outside working hours at 
the IOP, all patients attending the IOP during the study 
duration will be invited to participate in the survey.
Informed consent
In the first instance, the researchers will give an informa-
tion sheet to the patient, providing written and verbal 
information on the potential benefits and risks of taking 
part in the study and clarifying the assessments involved 
in the study. Only people who provided written informed 
consent will be included in the study. Where there are 
problems with literacy, the researchers will provide this 
information verbally to both the carer and the patient. 
Those unable to provide a signature will be requested 
to indicate their consent with a thumbprint. The infor-
mation sheet will meet all the requirements of the rele-
vant ethics committees. Maintenance of confidentiality 
and compliance with international, UK and relevant 
local Data Protection Acts will be emphasised to all study 
participants. Moreover, all participants will be informed 
that their participation in the study is voluntary, consent 
can be withdrawn at any stage and the decision about 
participation will not affect their care.
Mental capacity is time specific and decision specific. 
For patients who are assessed to lack capacity by their 
local physician, seeking informed consent will be delayed 
until capacity is regained, if feasible. No assessments will 
be continued where the patient appears reluctant, even 
where patient consent has been obtained.
Optional ‘consent to contact’ about future studies will 
be sought from survey participants. Permission will be 
sought to retain participant details and to contact partici-
pants about future studies that may be relevant for them. 
Again, it will be emphasised that this is voluntary, they can 
withdraw permission at any time and this will not affect 
their care in any way. After consenting to participate, 
the participant will be given a unique patient identifier 
(ID) by the researcher. The patient consent and contact 
information will be entered into a database (participant 
log), which will be kept separate from the survey result 
database. The survey result database will include only the 
unique patient ID and no patient identifiable data.
Confirmation of eligibility
SMI diagnosis will be confirmed by trained researchers 
using the relevant modules from the Mini- International 
Neuropsychiatric Interview (MINI) V.6.0.26 The MINI is 
a short diagnostic structured interview to explore mental 
disorders. It is designed to allow administration by non- 
specialist interviewers.27 The inter- rater reliability for the 
MINI will be assessed at each site at the start of the study. 
Within each study site, at least 10 MINI questionnaires 
will be completed and compared between two different 
researchers blinded from each other. Where needed, 
further training will be offered to achieve acceptable 
inter- rater reliability before researchers are assigned to 
the study.
Data collection
We will conduct a face- to- face digital survey to collect 
information about physical health and health- risk 
behaviours, severity of common mental disorders and 
health- related quality of life using validated instruments 
as described below. The survey has been translated into 
the most common languages in the countries (Urdu in 
Pakistan, Bangla in Bangladesh and Hindi, Kannada, 
Tamil and Telugu in India). The team of interviewers 
in each county will include men and women and will 
include researchers who speak regional dialects, which is 
consistent with usual clinical practice in these settings.28 
Participants will be able to express a preference to be 
interviewed by a researcher of the same gender, to reduce 
response bias that might arise due to the gender of the 
interviewer.
The WHO STEPwise approach to Surveillance (STEPS) 
instrument V. 3.2 will be used to collect information 
about non- communicable diseases and related health- 
risk behaviours.29 STEPS is an international standardised 
tool that will allow comparisons with the general popu-
lation within the country and between countries.30 The 
instrument has already been translated, used and vali-
dated in the general population in Bangladesh, India and 
Pakistan.31–33
To allow patients to disclose information on sexually 
transmitted diseases, HIV diagnosis, alcohol and tobacco 
consumption, in agreement with patient’s wishes, the 
interviewer will ask the caregivers/attendants to leave the 
room for this part of the interview.
Demographic information
The STEPS demographic module will be used to collect 
information on age, sex, education, marital status, 
employment, household assets and income.29
Mental health
We will collect information relevant to the SMI diagnosis 
of each participant, including duration of the mental 
illness, any treatment or medication and duration of the 
treatment and/or medication. The 9- item depression 
module (Patient Health Questionnaire-9 (PHQ-9))34 will 
be used to measure the severity of depressive symptoms 
and the generalised anxiety disorder 7- item scale (GAD-
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Health risk behaviours
The STEPS tobacco modules will be used to assess 
tobacco- related behaviours.29
Alcohol consumption
The STEPS alcohol module will be used to determine life-
time abstainers, past 12 months abstainers and current 
users of alcohol using the WHO cut- off scores.29
Diet
The STEPS diet module will be used to record the number 
of days that respondents consumed fruit and vegetables 
in a typical week, and the number of servings of fruit and 
vegetables consumed on average per day.36
Physical activity
The STEPS physical activity module will be used to record 
activity for transport purposes (eg, walking, cycling), 
vigorous and moderate activity at work and vigorous and 
moderate activity in leisure time and time spent sitting. 
Show cards with culturally relevant examples will be used 
to aid respondents in classifying activities. Analysis and 
categorisation will follow the WHO guidelines.37
Non-communicable diseases
Any medically diagnosed history of raised blood pres-
sure (BP), heart disease, hypercholesterolemia and 
high blood glucose, and treatment advised by a health 
worker for these diseases (such as prescribed medicines, 
a special diet, advice to reduce salt intake, lose weight, 
stop smoking or do more exercise) will be collected using 
the STEPS module for non- communicable diseases. Lung 
disease is not included in the STEPSs survey. However, 
it will be recorded asking the same set of questions as 
the non- communicable diseases included in the STEPS 
survey.
Infectious diseases
Self- report of medically diagnosed history of hepatitis B, 
C, syphilis, tuberculosis, HIV and intestinal parasites will 
be recorded.
Risk behaviours related to sexually transmitted diseases
Risk behaviours related to sexually transmitted diseases 
will be assessed using three questions that examine the 
presence of multiple sexual partners, unprotected sexual 
contact and use of injectable drugs that have been adapted 
from the 10- item HIV risk Screening Instrument.38 This 
instrument has been previously used in research involving 
persons with SMI in India.39
Health-related quality of life
The EQ- 5D- 5L will be used to measure health- related 
quality of life.40 41 The EQ- 5D- 5L is a standardised measure 
of health status, it provides a simple, generic measure of 
health for clinical and economic appraisal. The impact 
of disease/disorder is characterised on five dimensions 
(mobility, self- care, ability to undertake usual activities, 
pain and anxiety/depression). The EQ- 5D- 5L further 
assesses a patient’s subjective evaluation of their health 
state based on a visual analogue scale (EQ- 5D- VAS) 
between ‘0—worst imaginable health state’ and ‘100—
best imaginable health state’. We will use validated trans-
lations provided by EurOQol.
BP and heart rate
BP and pulse rate will be taken three times using an 
automated BP measuring instrument (OMRON). For BP 
measurement, the participant must be comfortable and 
rested. If he/she had been exerting themselves, then 
there will be a minimum of a 15 min rest period before 
the recording is taken. There should be at least a 3 min 
gap between the BP recordings. The procedure will follow 
the stepwise instructions in the WHO STEPS surveillance 
manual.42
Height weight and waist circumference
Height will be measured to a precision of 0.1 cm using a 
portable height measuring board without footwear and 
headgear. Weight will be measured in kilograms using 
a portable weighing scale placed on a firm flat surface 
with light clothing and without footwear and socks. Waist 
circumference will be measured in a precision of 0.1 cm, 
using a flexible fibreglass anthropometric tape at the end 
of normal expiration, at the midpoint between the lower 
margin of the last palpable rib and the top of the iliac 
crest (hip bone), with the arms relaxed at the sides. All 
measurements will be taken in duplicate and the average 
of the two values will be recorded and the protocols of the 
WHO STEPS surveillance manual will be followed.42
Biochemical analysis
A blood sample (8–9 mL) will be taken from consenting 
participants for glycated haemoglobin (HbA1c), lipid 
profile (triglycerides, total cholesterol, high- density lipo-
proteins (HDL), low- density lipoproteins (LDL)), thyroid 
function tests (includes thyroid hormones (T3, T4), 
thyroid stimulating hormone (TSH)), liver function tests 
(total bilirubin, aspartate transaminase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), 
total protein, albumin, albumin to globulin ratio), creati-
nine and haemoglobin.
Data management
To ensure quality of collected data, validation, checking, 
proofing and cleaning procedures will be carried out 
according to standard procedures.43 All consent forms 
will be stored separately from survey data in locked cabi-
nets in locked offices at study research offices at each 
study site. All coded data will be transferred to and stored 
as anonymous data at the University of York, which will 
act as the data curator. A secure password protected and 
encrypted electronic database will be set up to store the 
data.
Statistical analysis
Quantitative data will be summarised using descriptive 
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long- term physical health conditions (eg, diabetes, heart 
disease) and health- risk behaviours for type II diabetes, 
cardiovascular and respiratory disorders (eg, tobacco 
use, obesity, physical activity, diet) will be estimated in 
the SMI population. Second, we will examine the associa-
tions between physical health conditions and health- risk 
behaviours, using regression models with random inter-
cepts for data collection site with the following potential 
covariates: demographic variables (ie, age, sex and level 
of education), history of mental and physical conditions 
and biomarkers (eg, body mass index, BP). These regres-
sion models will also be used to calculate prevalence rates 
of physical health conditions and health- risk behaviours 
adjusted for these covariates (eg, for comparison with 
external general population data). Further regression 
analyses will explore the association between mental and 
physical health conditions and health- related quality of 
life measured using EQ- 5D- 5L. Regression models will 
take account of the nature and distribution of data (eg, 
count vs continuous data; skewed vs normally distributed 
data). To investigate the prevalence of physical health 
conditions and health risk behaviours in the general 
population, we will extract aggregated data on the preva-
lence of physical health conditions, health risk behaviours 
and lifestyle advice from the last available WHO STEPS 
survey from Bangladesh,44 India45 and Pakistan.46
ETHICS AND DISSEMINATION
The study has been approved by the ethics committees 
of the Department of Health Sciences University of 
York (UK), Centre for Injury Prevention and Research 
(Bangladesh), Health Ministry Screening Committee and 
Indian Council of Medical Research (India) and National 
Bioethics Committee (Pakistan).
The study will adhere to the fundamental principles of 
human rights and dignity laid down in the Declaration of 
Helsinki.47 Study procedures will comply with legislation 
and guidance for good practice governing the participa-
tion in research of people lacking capacity as set out in 
the Mental Capacity Act (UK) 2005.48 Participants will not 
receive any financial inducement to participate, but the 
results of the physical measurements and blood tests will 
be shared with the participant and the treating clinician.
As a non- interventional study, there is minimal risk 
of adverse events associated with the study. Due to the 
vulnerability of the SMI population, however, there is a 
potential (although low) risk that some questions or the 
burden of the assessments may cause distress for partici-
pants or the family carers. If there is any indication of this, 
the survey or assessments will be stopped, the participant 
offered reassurance and support, and if needed, referral 
to the clinical team. If a participant during the interview 
reveals any suicidal ideation, the interviewer will refer 
them to the treating clinician for a clinical risk assessment 
and further management. If a physical condition or blood 
test abnormality (outside the normal range for age and 
sex) is detected as a part of the research assessments, the 
research team will inform the clinician responsible for the 
patient, who will evaluate the result and give the patient 
the option of referral to a specialist if this is required for 
their condition.
Community, patient and public involvement
A ‘Community Panel’ comprising stakeholders from 
these constituencies ensures community, patient 
and public involvement. The panel has reviewed the 
planned survey and advised on its feasibility. The panel 
will continue to provide feedback on the conduct of the 
study and presentation of findings. To support dissemi-
nation efforts, findings will be presented to the commu-
nity panel, with advice sought about the format and 
content of lay summaries and other outputs aimed at 
patients and the public.
Dissemination
Findings will be disseminated in peer- reviewed articles, 
in local and international conferences and as reports for 
policymakers and stakeholders in the countries involved. 
An open access repository of all materials will be built that 
covers the survey materials as well as statistical syntax used 
by the team publications.
DISCUSSION
People with SMI have a reduced life expectancy. 
Research in HICs has shown that a large proportion of 
this inequality is accounted for by chronic diseases.1 2 
This has been consistently observed in HICs.3 4 However, 
information is lacking in minority groups and LMICs, 
which is surprising considering the increased risk of 
physical health conditions in these populations due 
to poverty, education, poor diet, low access to health-
care, exposure to infectious diseases and other envi-
ronmental factors.49 This survey will address this gap in 
knowledge, demonstrating the prevalence of different 
physical health conditions and health- risk behaviours in 
the SMI population and the association of each of these 
conditions in terms of health- related quality of life. It 
will support SMI clinical trial readiness by providing 
evidence- based findings regarding outcome measures 
and procedures relevant for clinical trial design.
Strengths and limitations
To the best of the authors’ knowledge, this will be the first 
large- scale study to investigate the physical health and 
health- risk behaviours in the SMI population in LMICs. 
The main limitation is that the survey is conducted in 
specialist centres (with patients with capacity) and is 
therefore a healthcare utilisation sample drawn largely 
from tertiary care. The gaps in treatment and care util-
isation and systematic factors influencing these have 
been well documented,50 therefore, the study popula-
tion may not be representative of the total SMI popu-
lation in each country. However, a community survey 
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mental health services are not sufficiently developed 
to be used to recruit participants for this survey (see, 
eg, work by PRIME15 and Emerald51 programmes on 
strengthening these services as access points). However, 
unlike services in HICs, tertiary care services in these 
South Asian countries accept self- referral without the 
need for primary or secondary care referral and we 
include outpatient services offered by the collabo-
rating centres which often function as ‘the first port 
of call’ for people with mental illness.52–54 Therefore, 
the selected centres are likely covering a broad range 
of the treatment- seeking population. We will not have 
a control group since the study is only conducted in 
people with SMI, however we are using the same ques-
tions and measurements as the WHO STEPS survey. 
This will allow us to compare the prevalence of physical 
health conditions and health risk behaviours with that 
of a survey representative for the population in each 
country.
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